EGb 761
Alternative Names: GBE 761; Gingogink; Ginkgo biloba special extract - Dr Wilmar Schwabe Group/Ipsen; Tanakan; Tebonin; Tebonin® konzent; TramisalLatest Information Update: 05 Nov 2023
At a glance
- Originator Dr. Willmar Schwabe Pharmaceuticals
- Developer Dr. Willmar Schwabe Pharmaceuticals; Ipsen
- Class Antidementias; Antiplatelets; Herbal medicines; Phytotherapies
- Mechanism of Action Antioxidants; Nitric oxide synthase type II inhibitors; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Alzheimer's disease; Cognition disorders; Ear disorders; Eye disorders; Neurological disorders; Vascular disorders
- No development reported Friedreich's ataxia; Tinnitus; Vertigo
- Discontinued Pancreatic cancer
Most Recent Events
- 08 Apr 2021 No recent reports of Phase-II development identified for Vertigo in Poland (PO)
- 08 Apr 2021 No recent reports of Phase-II development identified for Tinnitus in Poland (PO)
- 08 Apr 2021 No recent reports of Phase-III development identified for Tinnitus in Czech Republic (PO)